Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
huntingonthebluffs
Posts: 139
Joined: Wed Feb 24, 2016 12:00 am

Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

Post by huntingonthebluffs » Sun Jun 16, 2019 6:49 pm

FAVORABLE OVERALL SURVIVAL OF IMETELSTAT-TREATED RELAPSED/REFRACTORY MYELOFIBROSIS PATIENTS COMPARED WITH CLOSELY MATCHED REAL WORLD DATA

https://library.ehaweb.org/eha/2019/24t ... imetelstat

Ryan
Posts: 45
Joined: Sat Jul 08, 2017 1:41 pm

Re: Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

Post by Ryan » Sun Jun 16, 2019 7:58 pm

Thanks for posting.

The statistical superiority of Imetelstat is not only clear but profound.

We’re talking about over a year-and-a-half of continued life, that most key of KPI metrics.

It’s not if but when Imetelstat is approved on this indication, and I suppose the when is early next year but even that seems too far away.

Ryan
Posts: 45
Joined: Sat Jul 08, 2017 1:41 pm

Re: Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

Post by Ryan » Sun Jun 16, 2019 8:55 pm

PS - 65% lower risk of death

Imetelstat is superior to Best Available Therapy for R/R patients in MF, that can be stated unequivocally.

huntingonthebluffs
Posts: 139
Joined: Wed Feb 24, 2016 12:00 am

Re: Dr. Andrew Kuykendall presents IMbark results at 2019 EHA meeting

Post by huntingonthebluffs » Mon Jun 17, 2019 6:14 pm

For completeness, here are the links to the Geron 6/17/19 press release and the IMBark poster presentation. Note that the poster presentation link from my initial posts may be more usable as the various sections will enlarge when clicked on.

http://ir.geron.com/news-releases/news- ... s-european

https://www.geron.com/file.cfm/53/docs/ ... 0FINAL.pdf

Post Reply